In neuron-GBM interactions, the engineered peptide K90-114TAT disrupts the EAG2–Kvβ2 potassium channel complex, effectively attenuating tumor growth and invasion by targeting a key pathway in glioblastoma progression [106]. Here, KCNA3 is linked to neoplasm.